Prevalence, incidence and survival of heart failure: a systematic review

Abstract

Studies of the epidemiology of heart failure in the general population can inform assessments of disease burden, research, public health policy and health system care delivery. We performed a systematic review of prevalence, incidence and survival for all available population-representative studies to inform the Global Burden of Disease 2020. We examined population-based studies published between 1990 and 2020 using structured review methods and database search strings. Studies were sought in which heart failure was defined by clinical diagnosis using structured criteria such as the Framingham or European Society of Cardiology criteria, with studies using alternate case definitions identified for comparison. Study results were extracted with descriptive characteristics including age range, location and case definition. Search strings identified 42 360 studies over a 30-year period, of which 790 were selected for full-text review and 125 met criteria for inclusion. 45 sources reported estimates of prevalence, 41 of incidence and 58 of mortality. Prevalence ranged from 0.2%, in a Hong Kong study of hospitalised heart failure patients in 1997, to 17.7%, in a US study of Medicare beneficiaries aged 65+ from 2002 to 2013. Collapsed estimates of incidence ranged from 0.1%, in the EPidémiologie de l’Insuffisance Cardiaque Avancée en Lorraine (EPICAL) study of acute heart failure in France among those aged 20–80 years in 1994, to 4.3%, in a US study of Medicare beneficiaries 65+ from 1994 to 2003. One-year heart failure case fatality ranged from 4% to 45% with an average of 33% overall and 24% for studies across all adult ages. Diagnostic criteria, case ascertainment strategy and demographic breakdown varied widely between studies. Prevalence, incidence and survival for heart failure varied widely across countries and studies, reflecting a range of study design. Heart failure remains a high prevalence disease among older adults with a high risk of death at 1 year.

Deletion of the Lmna gene in fibroblasts causes senescence-associated dilated cardiomyopathy by activating the double-stranded DNA damage response and induction of senescence-associated secretory phenotype

“…Heart failure is a major cause of mortality and morbidity in the world, affecting over 60 million people globally [ 1 , 2 ] . Hereditary cardiomyopathies are major causes of heart failure and sudden cardiac death [ 1 , 3 ] .…”

“…Heart failure is a major cause of mortality and morbidity in the world, affecting over 60 million people globally [ 1 , 2 ] . Hereditary cardiomyopathies are major causes of heart failure and sudden cardiac death [ 1 , 3 ] . Hereditary dilated cardiomyopathy (DCM) comprises a genetically heterogeneous group of disorders characterized by cardiac dilatation and systolic dysfunction [ 4 ] .…”

Novel diagnostic potential of miR-1 in patients with acute heart failure

“…The prevalence of heart failure in 2020 was over six million patients in the United States of America (U.S.A), which is estimated to rise to more than eight million patients by 2030 [3]. The timely and accurate diagnosis of AHF and distinguishing it from chronic heart failure (CHF) are of great importance [4][5][6]. However, it is not always feasible to make a definite diagnosis merely based on history, physical examination, and echocardiogram [7].…”

Clinical Characteristics, Management, and In-Hospital Mortality in Patients with Heart Failure with Reduced Ejection Fraction According to Sex and the Presence of Type 2 Diabetes Mellitus

“…Heart failure (HF) is a prevalent disease primarily affecting elderly individuals [1,2]. The prognosis of heart failure is related to sex, age, etiology, left ventricular ejection fraction (EF), and comorbidities.…”

“…Abstract: Background: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of heart failure with reduced ejection fraction (HFrEF). Aims: (1) To describe and compare the clinical characteristics and the use of diagnostic and therapeutic procedures among subjects hospitalized with HFrEF according to the presence of type 2 diabetes mellitus (T2DM) and sex; (2) to assess the effect of T2DM and sex on hospital outcomes among the patients hospitalized with HFrEF using propensity score matching (PSM); and (3) to identify which clinical variables were associated to in-hospital mortality (IHM) among the patients hospitalized with HFrEF and T2DM according to their sex. Methods: A retrospective cohort study from 2016 to 2019 using the Spanish National Hospital Discharge Database was conducted.…”